Stock Analiz

Pyxis Oncology, Inc. PYXS

Biotechnology: Pharmaceutical Preparations · IPO 2021 · data as of November 13, 2026

$1.58Market cap $189M
Open the interactive analysis →

Pyxis Oncology, Inc. (PYXS) is a healthcare company listed in the US with a market value of about $189M. In the twelve months to September 30, 2026 it had revenue of $11M and net income of -$87M, a net margin of -785.5%.

Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -55%.

About Pyxis Oncology

Pyxis Oncology is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2021. It was profitable in 0 of the last 6 years in our data. Its share count rose by 88% over three years (dilution for shareholders). It spends 532% of revenue on research and development.

Score: 0.6 / 5

Value0/5
Future growth1/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S17.1
P/B4.6
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-37.5%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)-14.2%
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-526.8%
ROIC (5-yr avg.)-54.8%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 6 years

Fiscal yearTTM202520242023202220212020
Revenue$11M$14M$16M————
Net income-$87M-$80M-$77M-$74M-$121M-$76M-$13M
Free cash flow-$71M-$64M-$58M-$77M-$96M-$36M-$12M
EPS (diluted)$-1.27$-0.64$-0.66$-0.93$-1.82$-4.47$-6.22
Net margin-785.5%-574.5%-479.0%————
ROIC—-92.5%-61.8%-44.2%-54.3%-21.1%—

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 9 analysts is $8.22, 420% above the current price; targets range from $5.00 to $19.00; the consensus rating is “Strong buy”; expected EPS is $-1.08 for the fiscal year ending December 31, 2026.

Frequently asked questions

Does Pyxis Oncology pay a dividend?

Not currently.

Is Pyxis Oncology a good stock to buy?

We do not give buy or sell advice. Pyxis Oncology scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.